|
注册号: Registration number: |
ChiCTR2600122339 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-13 08:27:39 |
|
注册时间: Date of Registration: |
2026-04-13 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
心力衰竭诊治的多中心前瞻性队列研究 |
|
Public title: |
Multicenter Prospective Cohort Study on the Diagnosis and Management of Heart Failure |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
心力衰竭诊治的多中心前瞻性队列研究 |
|
Scientific title: |
Multicenter Prospective Cohort Study on the Diagnosis and Management of Heart Failure |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
晏露 |
研究负责人: |
王伟 |
|
Applicant: |
Yan Lu |
Study leader: |
Wang Wei |
|
申请注册联系人电话: Applicant telephone: |
+86 23 6876 5491 |
研究负责人电话:
Study leader's |
+86 23 6876 5491 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
Ripple_Yan@163.com |
研究负责人电子邮件: Study leader's E-mail: |
weiericwang@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市沙坪坝区新桥街道83号 |
研究负责人通讯地址: |
重庆市沙坪坝区新桥正街83号 |
|
Applicant address: |
No. 83, Xinqiao Subdistrict, Shapingba District, Chongqing City |
Study leader's address: |
No. 83, Xinqiao Subdistrict, Shapingba District, Chongqing City |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国人民解放军陆军军医大学第二附属医院 |
||
|
Applicant's institution: |
The Second Affiliated Hospital of the Army Medical University |
||
|
研究负责人所在单位: |
中国人民解放军陆军军医大学第二附属医院 |
||
|
Affiliation of the Leader: |
The Second Affiliated Hospital of the Army Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2026-研第041-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军陆军军医大学第二附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Second Affiliated Hospital of Army Medical University PLA |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-02-03 00:00:00 | ||
|
伦理委员会联系人: |
胡岚岚 |
||
|
Contact Name of the ethic committee: |
Hu Lanlan |
||
|
伦理委员会联系地址: |
重庆市沙坪坝区新桥正街83号 |
||
|
Contact Address of the ethic committee: |
No. 83, Xinqiao Subdistrict, Shapingba District, Chongqing City |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 68755422 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
35341579@qq.com |
|
研究实施负责(组长)单位: |
中国人民解放军陆军军医大学第二附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Affiliated Hospital of the Army Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市沙坪坝区新桥正街83号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 83, Xinqiao Subdistrict, Shapingba District, Chongqing City |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
重庆市技术创新与应用发展专项重点项目;干细胞及转化研究 |
||||||||||||||||||||||
|
Source(s) of funding: |
Technology Innovation and Application Development Key Project in Chongqing;National Key Research and Development Program |
||||||||||||||||||||||
|
研究疾病: |
心力衰竭 |
||||||||||||||||||||||
|
Target disease: |
Heart Failure |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
心力衰竭专病队列建设与多模态数据库构建 建立心力衰竭专病队列,系统采集多维度数据,包括流行病学数据、临床诊疗全流程数据、影像学数据、心理社会及环境暴露数据。通过整合上述多源异构数据,构建覆盖心力衰竭全周期的研究平台。为心力衰竭的精准分型、预后评估、全程管理提供资源支撑,助力临床诊疗决策优化和科研攻关。 次要目的:基于维度数据构建多模态融合的 心力衰竭人工智能疾病诊断和治疗评估模型。 通过整合临床数据、结合现有辅助检查的影像学资料,筛选具有预测价值的预后评估生物标志物,实现心力衰竭个体化风险评估、精准干预以及全周期管理。 |
||||||||||||||||||||||
|
Objectives of Study: |
Construction of a Heart Failure Disease-Specific Cohort and Development of a Multimodal Database A dedicated cohort for heart failure has been established, with systematic collection of multi-dimensional data, including epidemiological data, comprehensive clinical diagnosis and treatment records, imaging data, as well as psychosocial and environmental exposure data. By integrating these multi-source heterogeneous datasets, a research platform spanning the entire disease cycle of heart failure has been developed. This platform provides foundational support for precise subtyping, prognostic evaluation, and holistic management of heart failure, thereby facilitating optimized clinical decision-making and advancing scientific research. Secondary Objective: To develop an artificial intelligence-driven diagnostic and therapeutic evaluation model for heart failure based on multidimensional data fusion. By integrating clinical data and existing auxiliary imaging examinations, predictive biomarkers for prognosis assessment will be identified, enabling individualized risk stratification, precise intervention, and lifelong disease management for heart failure patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.妊娠或哺乳期妇女; 2.任何疾病晚期致预期寿命<6个月; 3.预期不能完成随访。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Pregnant or lactating women; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-04-01 00:00:00至 To 2030-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-04-13 00:00:00 至 To 2029-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF;EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF;EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |